Pharmacogenetics and pharmacogenomics: Recent developments, their clinical relevance and some ethical, social, and legal implications

Journal of Molecular Medicine

Volumn 81, Issue 3, 2003, Pages 135-140

  Paul, Norbert W ^a,b   Roses, Allen D ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Ethics; Medical genomics; Pharmacogenetics; Pharmacogenomics; Social accountability

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL MEDICINE; CLINICAL RESEARCH; CLINICAL STUDY; DIAGNOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ECONOMICS; ETHICS; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HUMAN; LEGAL ASPECT; MEDICAL GENETICS; MEDICAL PRACTICE; METABOLISM; MODEL; MOLECULAR BIOLOGY; NONHUMAN; PERFORMANCE; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL ASPECT;

EID: 0037362097     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-002-0415-6     Document Type: Review

References (43)

1. Paul NW (2001) Anticipating molecular medicine: smooth transition from biomedical science to clinical practice? Am Fam Physician 63:1704-1706
2. Weatherall D (1999) From genotype to phenotype: genetics and medical practice in the new millennium. Philos Trans R Soc Lond B Biol Sci 3541995-2010
3. Emilien G, et al (2000) Impact of genomics on drug discovery and clinical medicine. Q J Med 93:391-423
4. Dawson E (1999) New collaborations make pharmacogenomics a SNP. Mol Med Today 5:280
5. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491
6. Paul NW (2000) Die molekulargenetische Interpretation des Krebs: ein Paradigma, seine Entwicklung und einige Konsequenzen/The molecular interpretation of cancer: a paradigm, a story, some consequences. In: Eckard W (ed) 100 years of organized cancer research. Thieme, Stuttgart, pp 95-100
7. International SNP Map Working Group (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933
8. Sotos JG, et al (2000) Will genetics revolutionize medicine? N Engl J Med 343:1496-1498
9. Aparicio SAJR (2000) How to count human genes. Nat Genet 25:129-130
10. Ewing B, Green P (2000) Analysis of expressed sequence tags indicates 35:000 human genes. Nat Genet 25:232-234
11. Holtzman NA, Marteau TM (2000) Will genetics revolutionize medicine? N Engl J Med 343:141-144
12. Roses AD (1997) Genetic testing for Alzheimer disease. Practical and ethical issues. Arch Neurol 54:1226-1229
13. Rothman N, et al (2001) The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 2:C1-C10
14. Bader JS (2001) The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2:11-24
15. Sauer S, et al (2000) A Novel procedure for efficient genotyping of single nucleotide polymorphisms. Nucleic Acids Res 28:E13
16. Shi MM, Bleavins MR, de la Iglesia FA (1999) Technologies for detecting genetic polymorphisms in pharmacogenomics. Mol Diagn 4:343-351
17. Kwok PY (2000) High-throughput genotyping assay approaches. Pharmacogenomics 1:95-100
18. Roses AD (2000) Pharmacogenetics and future drug development and delivery. Lancet 355:1358-1361
19. Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature 405:857-865
20. Gura T (2001) Genetics. SNP-ing drugs to size. Science 293:595
21. Judson R, Stephens JC, Windemuth A (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics 1:15-26
22. Judson R, Stephens JC (2001) Notes from the SNP vs. haplotype front. Pharmacogenomics 2:7-10
23. McCarthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18:505-508
24. Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56:247-258
25. Riley JH, et al (2000) The use of single nucleotide polymorphisms in the isolation of common disease genes. Pharmacogenomics 1:39-47
26. The SNP Consortium (2000) Genotyping technology products user requirements survey (http://snp.cshl.org/news/user_survey.pdf)
27. Shi MM (2002) Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes. Am J Pharmcogenomics 2:197-205
28. Rothstein MA, Epps PG (2001) Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2:228-231
29. Rioux PP (2000) Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health-Syst Pharm 57:887-898
30. Clayton EW, et al (1995) Informed consent for genetic research on stored tissue samples. JAMA 274:1786-1792
31. Murphy MP (2000) Current pharmacogenomic approaches to clinical drug development. Pharmacogenomics 1:115-123
32. Clinton B (2000) On human subjects in clinical trials. Press Office of the President of the United States, Washington
33. Daly G (1991) The discursive construction of economic space: logics of organization and disorganization. Econ Soc 23:173-200
34. Khoury MJ (1999) Human genome epidemiology (HuGE): translating advances in human genetics into population-based data for medicine and public health. Genet Med 1:71-73
35. Khoury MJ, Little J (2000) Human genome epidemiologic reviews: the beginning of something HuGE. Am J Epidemiol 151:2-3
36. Have H ten (1995) Medical technology assessment and ethics - ambivalent relations. Hastings Cent Rep 25:13-19
37. Gibbons M, et al (1994) The new production of knowledge. The dynamics of science and research in contemporary societies. Sage, London
38. Kleinman A (1980) Patients and healers in the context of culture: an exploration of the borderland between anthropology, medicine, and psychiatry. Comparative studies of health systems and medical care, no 3. University of California Press, Berkeley
39. Jordanova L (1995) The social construction of medical knowledge. Soc History Med 8:361-381
40. Canguilhem G (1989) The normal and the pathological. Zone, New York
41. Rosenberg CE, Golden JL (eds) (1992) Framing disease: studies in cultural history. Health and medicine in American society. Rutgers University Press, New Brunswick
42. Task Force on Genetic Testing (U.S.), Holtzman NA, Watson MS (1998) Promoting safe and effective genetic testing in the United States: final report of the Task Force on Genetic Testing. Johns Hopkins University Press, Baltimore
43. Chandler ADJ (1990) Scale and scope: the dynamics of industrial capitalism. Harvard University Press, Cambridge